Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers

NCT04553692 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

272

Enrollment

INDUSTRY

Sponsor class

Stopped Study terminated due strategic corporate pivot to focus on auto-immune indications

Conditions

Solid Tumor
Colorectal Cancer
Non Hodgkin Lymphoma
Sarcoma
Chondrosarcoma
Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia
Acute Myeloid Leukemia

Interventions

DRUG: Aplitabart (IGM-8444)
DRUG: FOLFIRI
DRUG: Bevacizumab (and approved biosimilars)
DRUG: Birinapant
DRUG: Venetoclax
DRUG: Gemcitabine
DRUG: Docetaxel
DRUG: Azacitidine

Sponsor

IGM Biosciences, Inc.